Why the study?
Does targeting the ACE2/Angiotensin-(1-7)/Mas receptor axis prevent or treat thrombotic diseases?
Does targeting the ACE2/Angiotensin-(1-7)/Mas receptor axis prevent or treat thrombotic diseases?
Answers are grounded in this paper and cite their sources.
The ACE2/Angiotensin-(1-7)/Mas receptor axis is highlighted as a potential novel therapeutic target for managing thrombotic diseases.
Despite many therapeutic advances leading to increasingly effective drug treatments, thrombotic events (such as ischaemic stroke, pulmonary embolism, deep venous thrombosis and acute myocardial infarction) still represent a major worldwide cause of morbidity and mortality. Remarkable effort has been made to identify new drug targets. There is growing evidence indicating that the recently described counter-regulator axis of the renin-angiotensin system (RAS), composed of Angiotensin-Converting Enzyme 2 (ACE2), Angiotensin-(1-7) and the Mas receptor, has protective effects against thrombosis. In addition, it could be considered as a promising target for treating or preventing this disease. In this narrative review, we focused on the recent findings of the role of the ACE2/Angiotensin-(1-7)/Mas axis on the haemostatic process and its therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Fraga‐Silva et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: